Something to think about...Something I can't stop thinking about is that the current market cap is around $585M assuming 112.5M shares outstanding at the current price.
Biotoscana was purchased for $369M CAD and Exelon was purchased for $217M CAD. Neither of which was purchased at a high multiple. Total purchases of those two assets = $586M
Excluding the recent debt deal, substract cash + equivalents and financial assets from Mcap and you get ~290M CAD for GBT and drugs.
585 - 145 - 150 = 290M
So, at today's price, buyers are getting those assets at $0.50 on the dollar for what was paid, which our frugal management team deemed worth the purchase.
Also, ~45M in cash from Ops is a return on that 290M of 15.5%
Either they way overpaid for those assets (as chianchin most definitely believes) or this is an unbelievable gift from the market. My money is on the latter.